<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964040</url>
  </required_header>
  <id_info>
    <org_study_id>N-38-2013</org_study_id>
    <nct_id>NCT01964040</nct_id>
  </id_info>
  <brief_title>Perineural Dexmedetomidine and Femoral Nerve Block</brief_title>
  <official_title>Perineural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>anesthesia department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>faculty of medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The duration of sensory block after single dose of long acting local anesthetics is not
      sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as
      clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine
      is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our
      knowledge, the use of Dexmedetomidine as adjuvant to local anesthetic was not previously
      reported for femoral nerve block.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure of this study will be the change of sensory block over time.</measure>
    <time_frame>intraoperatively every 5 minutes for the first 30 minutes of the operation, then postoperatively every 2 hours for 24hours</time_frame>
    <description>Over a period of 30 min after injection of the study medications, a blinded investigator will assess sensory block with pinprick test using a 3-point scale: 0 ═ complete loss of sensation, 1 ═ partial loss of sensation and 2 ═ normal sensation (10). Pinprick test will be done in comparison to the contralateral area at the sensory distribution of the femoral nerve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>onset of motor and sensory block</measure>
    <time_frame>up to 30 minutes after the end of injection</time_frame>
    <description>The onset time of sensory and motor block will be: &quot;the time elapsed between the end of injection and the development of complete block (score of 0 at all dermatomes or no movement of the quadriceps muscle.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>duration of motor block</measure>
    <time_frame>interval between time of injection and complete motor power recover</time_frame>
    <description>The duration of motor block will be defined as: &quot;the time interval between the end of injection and the complete recovery of motor power of the quadriceps muscle)&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (</measure>
    <time_frame>2hours post operative and for 24hours</time_frame>
    <description>Visual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (12) will be assessed at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>time of 1st request of rescue analgesia</measure>
    <time_frame>over the poatoperative 24hours</time_frame>
    <description>The time to the first request of rescue postoperative analgesic will be: &quot;the time interval between the onset of successful sensory block and the first request to postoperative analgesia&quot;</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Onset and Duration of Sensory and Motor Block of Femoral Nerve,</condition>
  <condition>Visual Analogue Pain Scores,</condition>
  <condition>Time to First Request of Rescue Analgesics,</condition>
  <condition>Total Morphine Consumption in 24 Hours</condition>
  <arm_group>
    <arm_group_label>group B: control bupivacaine group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-peri-DEX: Peri-neural Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-sys-DEX:Systemic Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block</intervention_name>
    <description>ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.
After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia</description>
    <arm_group_label>group B: control bupivacaine group</arm_group_label>
    <arm_group_label>Group B-peri-DEX: Peri-neural Dexmedetomidine</arm_group_label>
    <arm_group_label>Group B-sys-DEX:Systemic Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with ASA physical status I or II, scheduled for diagnostic knee
             arthroscopy

        Exclusion Criteria:

          -  Patients who are refusing regional block, patients with diabetic peripheral
             neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture
             site, and history of allergic reaction to study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anesthesia department-faculty of medicine-Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Abeer Ahmed</investigator_full_name>
    <investigator_title>lecturer of anesthesia</investigator_title>
  </responsible_party>
  <keyword>femoral nerve block</keyword>
  <keyword>peri-neural dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

